Arvinas, Inc. (ARVN) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Arvinas, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.436 Hello and welcome to the AirVenus 4Q25 earnings call. 00:00:03.436 -- 00:00:06.440 All lines have been placed on mute to prevent any background noise. 00:00:06.440 -- 00:00:09.845 After the speaker's remarks, there will be a question and answer session. 00:00:09.845 -- 00:00:13.049 If you would like to ask a question during this time, simply press star followed by the 00:00:13.049 -- 00:00:16.834 number one on your telephone keypad. And if you would like to withdraw your question, 00:00:16.834 -- 00:00:20.860 press star one again. Thank you. I will now turn the call over to Jeff Boyle, Head of 00:00:20.860 -- 00:00:23.964 Impressor Relations. Jeff, you may begin. 00:00:23.964 -- 00:00:26.373 Good morning, everyone, and thank you for joining us. 00:00:26.373 -- 00:00:31.199 Earlier today, we issued a press release with our fourth quarter and full year 2025 financial 00:00:31.199 -- 00:00:37.027 results, which is available in the investor and media section of our website at arvenis.com. 00:00:37.027 -- 00:00:41.833 Joining us on the call today, we have Randy Teal, our president and CEO, Noah Berkowitz, 00:00:41.833 -- 00:00:47.099 our chief medical officer, Angela Cacasey, our chief scientific officer, and Andrew Saik, 00:00:47.099 -- 00:00:51.865 our chief financial officer. Before we begin, I'll remind you that today's discussion 00:00:51.865 -- 00:00:56.056 contains forward-looking statements that involve risks, uncertainties, and assumptions. 00:00:56.056 -- 00:00:59.840 These risks and uncertainties are outlined in today's press release and in the company's 00:00:59.840 -- 00:01:04.344 recent filing with the Securities and Exchange Commission, which I urge you to read. 00:01:04.344 -- 00:01:08.688 Our actual results may differ m...